Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the development of the pipeline candidate, birtamimab. The decision to discontinue ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

Several presentations will highlight updated results from ongoing Phase 1 studies that inform the dosing strategy in ... of ELREXFIO in combination with daratumumab and lenalidomide in patients ...

Treatment discontinuation due to a TEAE occurred in 5.7% of patients on daratumumab. Dose modifications were required for 46.6% of patients. Based on an earlier assessment of AQUILA, the developer ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

Findings showed 60 percent reduction in risk of disease progression or death with daratumumab SC quadruplet regimen compared to current standard of care triplet regimen 1 “Optimising frontline therapy ...

Infusion charts will be completed to document compliance with prescribed ... the trial will continue with doses of 9 mg/kg and a higher daratumumab dose (eg, 12 or 16 mg/kg as determined by safety ...